Compare Medtronic PLC (MDT) vs ServiceNow Inc (NOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs ServiceNow Inc — how do they compare? Medtronic PLC trades at $87.9 (market cap $112.24B), while ServiceNow Inc trades at $139.85 (market cap $144.48B). The key difference: ServiceNow Inc is the larger of the two by market cap, and Medtronic PLC pays a 3.28% dividend while ServiceNow Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and ServiceNow Inc for 54 Days on average.
| MDT | NOW | |
|---|---|---|
Market Cap | $112.24B | $144.48B |
Volume | 105,663,236 | 11,801,699 |
Sector | Health | Technology |
52-Week High | $105.35 | $189.26 |
52-Week Low | $73.75 | $83.00 |
Typical Hold Time | 63 Days | 54 Days |
Enterprise Value | $131.58B | $148.27B |
Dividend Yield | 3.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $85.51, down 1.81% on the day, showing bearish technical signals despite strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters with Q3 2026 results pending, while maintaining robust profitability margins of 65% gross and 14% net. Recent news highlights the company's 49-year dividend growth streak and new product approvals, though technical indicators show selling pressure with the stock trading near support at $85.
MDT presents a compelling value opportunity with a 3.2% dividend yield and 14% upside to the $97.80 consensus target, though near-term technical weakness and increasing debt levels warrant caution. The company's consistent earnings beats and medical device market leadership support long-term growth, while regulatory approvals for new systems provide catalysts.
ServiceNow (NOW) trades at $139.75, up 1.29% with bullish technical momentum and strong institutional support. The company demonstrates robust revenue growth from $7.2B in 2022 to $13.3B in 2025, with consistent earnings beats and expanding AI capabilities driving investor optimism. Despite premium valuation metrics (P/E 86.17, P/S 9.75), the stock benefits from positive analyst sentiment with 87% buy ratings and a $146.04 consensus target.
NOW presents a compelling growth story with AI revenue surpassing $1B and projected to triple by 2029. However, elevated valuation multiples and competitive pressures from Atlassian and Palantir warrant caution. The stock's upside depends on sustained AI adoption and margin preservation amid increasing investment requirements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →
